Preparation of clinical‐grade 89Zr‐panitumumab as a positron emission tomography biomarker for evaluating epidermal growth factor receptor‐targeted therapy

摘要: Panitumumab is a fully human monoclonal antibody approved for the treatment of epidermal growth factor receptor (EGFR) positive colorectal cancer. Recently, panitumumab has been radiolabeled with 89Zr and evaluated its potential to be used as immuno-positron emission tomography (PET) probe EGFR cancers. Interesting preclinical results published by several groups researchers have prompted us develop robust procedure producing clinical-grade 89Zr-panitumumab an immuno-PET evaluate EGFR-targeted therapy. In this process, bio-conjugated desferrioxamine chelate subsequently resulting in high radiochemical yield (>70%, n = 3) purity (>98%, n = 3). All quality control (QC) tests were performed according United States Pharmacopeia specifications. QC showed that met all specifications injection. Herein, we describe step-by-step method facile synthesis medical use. The entire process bioconjugation, radiolabeling, will take about 5 h. Because manual, two rapid, in-process introduced make error free. Copyright © 2013 John Wiley & Sons, Ltd.